Elanco Animal Health Incorporated (ELAN) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

followed by the number one once again. Thank you. I would now like to hand the call over to Tiffany Kanega, Head of Investor Relations. You may begin your conference. Good morning. Thank you for joining us for Alanko Animal Health's first quarter 2025 earnings call. I'm Tiffany Kanega, Vice President of Investor Relations and ESG. Joining me on today's call are Jeff Simmons, our President and Chief Executive Officer, Todd Young, our Chief Financial Officer, and Beth Haney from Investor Relations. The slides referenced during this call are available on the Investor Relations section of elanco.com. Today's discussion will include forward-looking statements. These statements are based on our current assumptions and expectations and are subject to risks and uncertainties that could cause actual results to differ materially from our forecast. For more information, see the risk factors discussed in today's earnings press release, as well as in our Form 10-K and 10-Q filed with the SEC. We do not undertake any duty to update any forward-looking statements. Our remarks today will focus on our non-GAAP financial measures. Reconciliations of these non-GAAP measures are included in the appendix of today's slides and in the earnings press release. References to organic performance exclude the estimated impact of the aqua business, which was divested July 9th, 2024. After our prepared remarks, we will be happy to take your questions. I will now turn the call over to Jeff. Thanks, Tiffany. Good morning, everyone. Elanco exceeded first quarter guidance for revenue, adjusted EBITDA, and adjusted EPS. Continuing our momentum from the end of 2024, we've delivered a high-quality quarter with 4% organic constant currency revenue growth, evenly driven by price and volume. This strong Q1 ...